Gerhardt Attard, MD, PhD, FRCP, discusses niraparib plus abiraterone acetate and prednisone in mCSPC with HRR gene alterations.
Gerhardt Attard, MD, PhD, FRCP
Advertisement
Gerhardt Attard, MD, PhD, FRCP, is a professor of medical oncology in University College London in the UK.
Articles by Gerhardt Attard, MD, PhD, FRCP
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
3
Aligning Patient Goals and Toxicity Burden Are Key in First-Line Chemo Selection in Pancreatic Cancer
4
Novel Targeted Agents Are Poised to Influence the MPN Treatment Paradigm: With John O. Mascarenhas, MD
5